Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Apr 8, 2014
Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398

Mar 31, 2014
Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting

Stock Quote (NASDAQ: MACK)

Price:
4.52

Change:
+ 0.02

Day High:
4.65

Day Low:
4.41

Volume:
722,400

4:00 PM ET on Apr 17, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools